Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women

Trial Profile

Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir; Lamivudine; Lamivudine/zidovudine; Tenofovir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 21 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
    • 09 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top